AAD 2019—Risankizumab superior to ustekinumab in moderate-to-severe psoriasis


  • Marielle Fares, Pharm.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Analysis of 2 phase 3 UltlMMa-1 and UltlMMa-2 trials shows superior efficacy of risankizumab compared with ustekinumab in patients with moderate-to-severe psoriasis.

Why this matters

  • This study supports the use of risankizumab across several patient populations.

Key results

  • Risankizumab-treated patients scored significantly higher on the PASI90 and sGA 0/1 efficacy measures compared with ustekinumab (P<.001>
  • Baseline mean Psoriasis Area and Severity Index (PASI) scores and body surface involvement were similar in both patient groups.
  • At week 52, the proportion of patients achieving PASI90 and sGA 0/1 was significantly higher among patients receiving risankizumab compared with patients receiving ustekinumab.
    • PASI90 range (77.6%-85.9% in risankizumab vs 30.8%-56.3% in ustekinumab group).
    • sGA 0/1 range (79.5%-90.6% in risankizumab vs 39.4%-65.2% in ustekinumab group).
  • Results were consistent across all patient subgroups defined by baseline demographics, disease characteristics, and prior biologic response.
  • There were no new safety signals in this study, and the adverse event profile was similar in the risankizumab and ustekinumab groups.

Study design

  • 598 patients received risankizumab and 199 received ustekinumab. The amount of previous biologic therapy was similar in both groups.
  • Patients were randomly assigned 3:3:1 to receive risankizumab 150 mg, ustekinumab 45 or 90 mg, or placebo. Patients received injections at weeks 0, 4, 16, 28, and 40 (part A, weeks 0-4).
  • At week 16, placebo patients were switched to risankizumab 150 mg.
  • Patients received risankizumab or ustekinumab at weeks 16, 28, and 40 (part B, weeks 16-52).
  • Funding: AbbVie Inc.

Limitations

  • None.